Faecal calprotectin as a potential biomarker of disease severity in SARS-CoV-2 infection - 06/09/22
Doi : 10.1016/j.jinf.2022.06.016
N O'Moráin a, b, ⁎ 
, R Stack a, b, J Doherty a, b, M Tosetto a, A Garcia Leon c, P Mallon c, d, G Doherty a, b
on behalf of the
, R Stack a, b, J Doherty a, b, M Tosetto a, A Garcia Leon c, P Mallon c, d, G Doherty a, bon behalf of the
All Ireland Infectious Diseases (AIID) Study Group
a Centre for Colorectal Disease, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland
b School of Medicine, University College Dublin, Dublin, 4, Ireland
c Centre for Experimental Pathogen Host Research, University College Dublin, Dublin, 4, Ireland
d Department of Infectious Disease, St. Vincent's University Hospital, Dublin, 4, Ireland
⁎Corresponding author at: Centre for Colorectal Disease, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland.Centre for Colorectal DiseaseSt. Vincent's University HospitalElm ParkDublin 4Ireland
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Keywords : SARS-CoV-2 infection, COVID-19, Intestinal inflammation, Disease severity, Faecal calprotectin
Le texte complet de cet article est disponible en PDF.
| ☆ | This study has been approved by the Research Ethical Committee of St. Vincent's University Hospital |
| ☆☆ | PM and GD contributed to the conception and design of the study. NOM, MT and AGL contributed to the acquisition, analysis, and interpretation of data. NOM drafted the article. JD and RS contributed to critically revising the article. PM and GD contributed to revising the article and gave final approval of the version to be submitted. |
© 2022
The British Infection Association. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 85 - N° 4
P. 436-480 - octobre 2022 Retour au numéro
Article précédent
- No durable impact of COVID-19 measures on the hospital burden of respiratory syncytial virus (France, 2018–2022)
- Jacques Fourgeaud, Julie Toubiana, Hélène Chappuy, Christophe Delacourt, Florence Moulin, Perrine Parize, Anne Scemla, Hanene Abid, Marianne Leruez-Ville, Pierre Frange
- Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trial
- Suvimol Niyomnaitham, Zheng Quan Toh, Paul Vincent Licciardi, Patimaporn Wongprompitak, Kanjana Srisutthisamphan, Katherine Kradangna Copeland, Kulkanya Chokephaibulkit
Bienvenue sur EM-consulte, la référence des professionnels de santé.